Non-small cell lung cancer, BRAF-mutated
Jump to navigation
Jump to search
| Page editor | Section editor | ||
|---|---|---|---|
 |
Amit Kulkarni, MBBS University of Minnesota Minneapolis, MN  AmitKulkarniMD
|
 |
Travis Osterman, DO, MS, FAMIA Vanderbilt University Nashville, TN TravisOsterman |
Note: these are regimens tested in biomarker-specific populations, please see the main NSCLC page for other regimens.
3 regimens on this page
3 variants on this page
|
Advanced or metastatic disease, first-line
Dabrafenib & Trametinib
| back to top |
Regimen
| FDA-recommended dose |
| Study | Years of enrollment | Evidence |
|---|---|---|
| Planchard et al. 2017 (BRF113928-untreated) | 2014-2015 | Phase II (RT) |
Biomarker Eligibility Criteria
- Biomarker: BRAF V600E
Targeted therapy
- Dabrafenib (Tafinlar) 150 mg PO twice per day
- Trametinib (Mekinist) 2 mg PO once per day
Continued indefinitely
References
- BRF113928: Planchard D, Smit EF, Groen HJM, Mazieres J, Besse B, Helland Å, Giannone V, D'Amelio AM Jr, Zhang P, Mookerjee B, Johnson BE. Dabrafenib plus trametinib in patients with previously untreated BRAF(V600E)-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. Lancet Oncol. 2017 Oct;18(10):1307-1316. Epub 2017 Sep 11. link to original article PubMed NCT01336634
Advanced or metastatic disease, previously treated, BRAF inhibitor-naive
Dabrafenib & Trametinib
| back to top |
Regimen
| FDA-recommended dose |
| Study | Years of enrollment | Evidence |
|---|---|---|
| Planchard et al. 2016 (BRF113928-treated) | 2013-2015 | Phase II (RT) |
All enrolled patients had progressed on 1 to 3 prior regimens.
Biomarker Eligibility Criteria
- Biomarker: BRAF V600E
Targeted therapy
- Dabrafenib (Tafinlar) 150 mg PO twice per day
- Trametinib (Mekinist) 2 mg PO once per day
Continued indefinitely
References
- BRF113928: Planchard D, Besse B, Groen HJ, Souquet PJ, Quoix E, Baik CS, Barlesi F, Kim TM, Mazieres J, Novello S, Rigas JR, Upalawanna A, D'Amelio AM Jr, Zhang P, Mookerjee B, Johnson BE. Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. Lancet Oncol. 2016 Jul;17(7):984-93. Epub 2016 Jun 6. link to original article contains verified protocol link to PMC article PubMed NCT01336634